Verona Pharma plc
(“Verona Pharma” or the “Company”)
Director
Dealing
3 December 2015, Cardiff –
Verona Pharma plc (AIM: VRP) today received notification that
David Ebsworth, Director of the
Company, today purchased 370,000 ordinary shares of 0.1 pence each of the Company (“Ordinary Shares”)
at a price of 3.25 pence per Ordinary
Share.
Following the transaction David
Ebsworth has a total interest of 4,199,774 Ordinary Shares,
representing 0.42% of the total voting rights.
-Ends-
For further information please
contact:
| Verona Pharma plc |
Tel: +44 (0) 20 3283
4200 |
| Jan-Anders Karlsson, Chief Executive
Officer |
|
|
|
| N+1 Singer |
Tel: +44 (0)20 7496 3000 |
| Aubrey Powell / Jen Boorer |
|
|
|
| FTI Consulting |
Tel: +44 (0)20 3727 1000 |
| Simon Conway / Stephanie Cuthbert /
Natalie Garland-Collins |
|
Notes to Editors
About Verona Pharma plc
Verona Pharma plc is a UK-based clinical stage biopharmaceutical
company focused on the development of innovative prescription
medicines to treat respiratory diseases with significant unmet
medical needs, such as chronic obstructive pulmonary disease
(COPD), asthma and cystic fibrosis.
Verona Pharma's lead drug, RPL554, is a first-in-class drug
currently in Phase II trials as a nebulised treatment for acute
exacerbations of COPD in the hospital setting. The drug is a
dual phosphodiesterase (PDE) 3/4 inhibitor and therefore has both
bronchodilator and anti-inflammatory effects, which are essential
to the improvement of patients with COPD and asthma.
Verona Pharma is also building a broader portfolio of
RPL554-containing products to maximise its benefit to patients and
its value. This includes the very significant markets for
COPD and asthma maintenance therapy. The Company is also
exploring the potential of the drug in different diseases, such as
cystic fibrosis, where it is in pre-clinical testing and has
received a Venture and Innovation Award from the Cystic Fibrosis
Trust.